Aurora Cannabis Launches New European Websites, Showcasing Science-Backed Cannabis Leadership

Aurora Cannabis has launched four new websites tailored specifically to its European medical marijuana operations, part of a broader effort to deepen engagement with healthcare professionals, partners and patients across some of the continent’s most important markets. The new digital platforms include a central European hub that links directly to localized sites for Germany, the United Kingdom and Poland. Each site is presented in its native language and designed to reflect the company’s science-driven approach, manufacturing standards and regional presence.

According to Aurora, the updated websites are meant to better showcase its medical expertise, product portfolio and partnerships while creating a more accessible and locally relevant experience for visitors. The initiative aligns with the company’s long-term strategy of expanding its footprint in Europe, which it describes as its fastest-growing region. The central European site, www.auroramedicine.com, provides easy access to the dedicated regional sites for Germany, the UK, and Poland.

“Our new European websites are a demonstration of our ongoing investment and long-term commitment to Aurora’s fastest growing region,” said Andreas Dotterweich, Senior Vice President of Aurora Europe. “The sites leverage our global leadership in medical cannabis, putting our products, scientific expertise and partnerships front and centre, providing enhanced resources for healthcare practitioners and partners looking for a trusted resource.”

The refreshed sites also highlight Aurora’s manufacturing operations, including both Canadian production and European-based facilities, with updated videos and imagery emphasizing quality control, compliance and evidence-based processes.

Aurora says the centralized European hub allows seamless navigation between regional sites, helping unify its brand identity across markets while maintaining local relevance. The company views the move as part of a wider communications strategy intended to position it for continued growth as medical marijuana regulations and access expand throughout Europe.

Aurora operates GMP-certified production facilities in both Canada and Germany and serves medical markets across Europe, Australia and New Zealand in addition to Canada. The company maintains a medical-first focus while pursuing higher-margin opportunities internationally.